Health >> JAMA Current Issue

Menopausal Hormone Therapy for Prevention of Chronic Conditions

Link [2022-11-01 19:04:52]

Over the past 2 decades, the US Preventive Services Task Force (USPSTF) has issued 5 updates to its recommendation on menopausal hormone therapy (MHT), each time recommending against use of estrogen with or without a progestin for prevention of chronic conditions such as coronary heart disease (CHD). The first of these appeared in 2002, shortly after the first Women’s Health Initiative (WHI) trial enrolling more than 16 000 US women aged 50 to 79 years from 40 clinical centers reported an unfavorable overall benefit-to-risk ratio of postmenopausal estrogen with progestin for primary prevention of chronic diseases, followed by another update in 2005 after the WHI estrogen-only trial enrolling more than 10 000 additional women drew similar conclusions for unopposed estrogen. The next was in 2012, after findings from longer-term follow-up and subgroup analyses from the WHI and other smaller trials supported the same conclusions. In 2017, the task force reissued its recommendation, again based on substantially the same evidence.